【JP:286A】Stock Price

Yukaria is a company that operates diverse services in the medical, long-term care, and healthcare sectors. The company's core business is comprehensive management support for medical institutions, and it also handles admission consulting, operation of care facilities for elderly people, manufacturing and sales of contact lenses, analysis of treatment data, and support services for pharmaceutical companies. Its distinguishing feature is advancing operational improvements and business efficiency in partnership with frontline operations.

The company's primary customers are medical institutions such as hospitals and clinics, elderly people requiring care and their families, general consumers (contact lens purchasers), pharmaceutical companies, and financial institutions. Yukaria maintains multiple revenue streams including consulting fees, facility operation income, product sales, success-based referral fees for admissions, funding support and factoring income, and data and software licensing fees. The company secures projects consistently through networks with financial institutions and partner medical organizations.

The company's business is divided into four segments: comprehensive medical management support, senior-related business, highly regulated medical device business, and other operations (data analysis and pharmaceutical support). The medical management support division provides end-to-end services including management consulting, fundraising support, sale-and-leaseback arrangements, in-hospital digital transformation, human resources and procurement improvements, construction and renovation support, and business succession and M&A services. It also provides proprietary human resources and information terminal systems. The senior business operates a nationwide network for admission consulting (approximately 9,000 facilities) and manages company-operated facilities, while offering unique resident services such as dementia prevention programs, meal programs, and family information access services. The contact lens business, operated through a subsidiary, sells multiple brands including flagship silicone hydrogel products.

The company positions stable revenue growth and business expansion as pillars of its growth strategy. Currently, it directly supports 26 hospitals in healthcare institution services, has accumulated over 1 million treatment progress records as medical data, and partners with more than 10,000 senior care facilities nationwide. For investors, the company identifies revenue and net income as key performance indicators, and monitors EBITDA to demonstrate normalized earning power, along with the number of affiliated medical corporations, placement arrangements, and occupancy rates, aiming to enhance enterprise value over the medium to long term.

The company allocates resources to four priority investment areas: comprehensive healthcare management support, senior care services, contact lens manufacturing and sales, and medical data services. Its competitive advantages stem from a "hands-on, field-focused" support approach, project acquisition capabilities through networks with regional financial institutions and healthcare providers, and one-stop service delivery strengthened by proprietary solutions and external partnerships. Specifically, by providing integrated support spanning management analysis, human resources system design, construction cost optimization, and fundraising assistance, the company secures recurring revenue that single-engagement consulting cannot achieve.

For new market development and business expansion, the company plans to strengthen channels centered on regional banks and broaden its partner base by providing consulting to external medical corporations. The strategy involves expanding touchpoints with non-affiliated medical corporations to convert them into partners, while in senior care services, it is increasing placement counselors and entering underserved markets. The company also positions M&A as a growth tool, leveraging expertise gained from past acquisitions such as Clutch to pursue future acquisitions and partnerships in related fields, targeting early synergy creation.

Regarding technological innovation, the company is strengthening digital transformation (DX) and data utilization. Beyond supporting adoption of proprietary terminals and solutions such as "Yukaria Touch," it provides MR training software and marketing support for pharmaceutical companies based on a data lake constructed through analysis by data scientists. Additionally, the contact lens business began offering consulting in 2023 by leveraging product development and regulatory approval expertise, aiming to expand revenue opportunities by combining technology and data.